Literature DB >> 2803953

Cisplatin/carboplatin cross-resistance in ovarian cancer.

M E Gore1, I Fryatt, E Wiltshaw, T Dawson, B A Robinson, A H Calvert.   

Abstract

Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2803953      PMCID： PMC2247292          DOI： 10.1038/bjc.1989.356

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  15 in total

1.  Second trial drugs in ovarian cancer.

Authors:  C R Stanhope; J P Smith; F Rutledge
Journal:  Gynecol Oncol       Date:  1977-03       Impact factor: 5.482

2.  Ovarian trials at the Royal Marsden.

Authors:  E Wiltshaw
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

3.  Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.

Authors:  E Wiltshaw; T Kroner
Journal:  Cancer Treat Rep       Date:  1976-01

4.  Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy.

Authors:  H W Bruckner; C J Cohen; R C Wallach; B Kabakow; G Deppe; E M Greenspan; S B Gusberg; J F Holland
Journal:  Cancer Treat Rep       Date:  1978-04

5.  High-dose carboplatin in refractory ovarian cancer patients.

Authors:  R F Ozols; Y Ostchega; G Curt; R C Young
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

6.  A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.

Authors:  E Wiltshaw; B Evans; G Rustin; E Gilbey; J Baker; G Barker
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

7.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

Authors:  R J Knox; F Friedlos; D A Lydall; J J Roberts
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

8.  Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects.

Authors:  A D Lewis; J D Hayes; C R Wolf
Journal:  Carcinogenesis       Date:  1988-07       Impact factor: 4.944

9.  Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.

Authors:  B D Evans; K S Raju; A H Calvert; S J Harland; E Wiltshaw
Journal:  Cancer Treat Rep       Date:  1983-11

10.  Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.

Authors:  E Boven; W J van der Vijgh; M M Nauta; H M Schlüper; H M Pinedo
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701
View more
  30 in total

1.  Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides.

Authors:  K J Mellish; Y Qu; N Scarsdale; N Farrell
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

2.  A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

Authors:  Kathleen N Moore; Camille C Gunderson; Paul Sabbatini; D Scott McMeekin; Gina Mantia-Smaldone; Robert A Burger; Mark A Morgan; Ann M Kapoun; Rainer Karl Brachmann; Robert Stagg; Azeez Farooki; Roisin E O'Cearbhaill
Journal:  Gynecol Oncol       Date:  2019-06-04       Impact factor: 5.482

3.  Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

Authors:  L R Kelland; M Jones; G Abel; M Valenti; J Gwynne; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay.

Authors:  W Schroyens; P Dodion; M Rozencweig
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

5.  Structural basis for the bypass of the major oxaliplatin-DNA adducts by human DNA polymerase η.

Authors:  Hala Ouzon-Shubeita; Meghan Baker; Myong-Chul Koag; Seongmin Lee
Journal:  Biochem J       Date:  2019-02-28       Impact factor: 3.857

6.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.

Authors:  M J McKeage; P Mistry; J Ward; F E Boxall; S Loh; C O'Neill; P Ellis; L R Kelland; S E Morgan; B Murrer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 8.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

9.  Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.

Authors:  D K Kim; H T Kim; Y B Cho; J H Tai; J S Ahn; T S Kim; K H Kim; W S Hong
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 10.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.